在真实世界肝细胞癌中,二碳酸盐集成的跨动脉化学栓塞 (TACE)
Kai Jin1, Siying Zeng2,3, Bin Li1
1Interventional Radiology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Signal transduction and targeted therapy
|August 31, 2025
概括
对于肝细胞癌 (HCC) 的局部控制,TILA- TACE 的客观反应率为99%,明显优于传统治疗. 这种新疗法具有可容忍的安全性和生存益处,特别是在晚期的HCC中.
科学领域:
- 肝胆瘤学
- 干预性放射学
- 辐射瘤学
背景情况:
- 对肝细胞癌 (HCC) 进行常规的跨动脉化学栓塞 (TACE) 的客观反应率为局部控制的约50%.
- TILA- TACE是一种新型二碳酸盐集成的TACE,此前在局部控制不可切割的HCC方面表现出100%的有效性.
研究的目的:
- 在实际临床实践中验证TILA- TACE的疗效,选择性和安全性.
- 评估TILA- TACE与晚期HCC的放射治疗结合的结果,包括大血管侵袭和肝外转移.
主要方法:
- 总共413名HCC患者 (早期,中期和晚期) 参与了这项实践验证研究.
- TILA- TACE用于初级瘤治疗,而放射治疗用于宏血管侵袭和肝外转移.
- 系统地记录和分析了TILA- TACE的副作用.
主要成果:
- 在HCC瘤中,TILA- TACE的客观应答率为99. 01%,完全应答率为72. 77%.
- 放射治疗显示瘤血栓的客观反应率为96. 88%.
- 晚期HCC患者的中位生存期为27个月,肝内转移是癌症相关死亡的主要原因.
结论:
- TILA- TACE是一种高度有效和安全的新疗法,用于局部控制HCC,具有可容忍的安全性.
- 在晚期HCC患者中,TILA- TACE与放射治疗的结合提供了显著的生存益处.
- 需要进一步研究以解决肝脏内转移作为治疗后死亡的原因.
相关概念视频
Targeted Cancer Therapies
7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.0K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
689
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689


